Autophagy Machinery: Initiation to Lysosomal Fusion
Macroautophagy (autophagy; bulk and selective degradation; double-membrane phagophore → autophagosome (600–900 nm) → autolysosome fusion (LAMP1/2+RAB7 late endosome/lysosome); 5 stages: (1) initiation (ULK1 complex; ULK1/2 + ATG13 + FIP200/RB1CC1 + ATG101; mTORC1 phosphorylates ULK1 Ser757/Ser638/ATG13 Ser258 → complex dissolution → autophagy off; AMPK phosphorylates ULK1 Ser317/555/Ser467 → autophagy on; AMPK also phosphorylates mTORC1 suppressing component raptor → double activation)); (2) nucleation (Beclin-1/ATG6 + VPS34/PI3K-III + ATG14L (autophagy) or UVRAG (endosome/late autophagy) + VPS15 → PI3P generation at ER omegasome (ER contact site); PI3P → DFCP1/WIPI1/2 recruitment → phagophore membrane curvature; Beclin-1 regulation: BCL-2/BCL-XL (ER-localised) inhibit Beclin-1; JNK → BCL-2 Ser70 → BCL-2/Beclin-1 disruption → autophagy; AMBRA1 stabilises Beclin-1-VPS34)); (3) elongation/closure (two ubiquitin-like conjugation systems: ATG12-ATG5-ATG16L1 complex (ATG7 E1/ATG10 E2; forms WD40 scaffold; directs LC3 lipidation); LC3 (MAP1LC3A/B/C; PE-lipidation: ATG4B → pro-LC3 processing → LC3-I + ATG7 E1 + ATG3 E2 + ATG12-ATG5-ATG16L1 E3-like → LC3-II (PE-conjugated; autophagosome membrane; widely used autophagy marker))); (4) cargo recognition (p62/SQSTM1 (cargo receptor; UBA domain binds ubiquitinated substrates; LIR motif binds LC3-II; Keap1 interaction: p62 Ser349 → Keap1 competition → Nrf2 activation → p62 Nrf2 feed-forward); NBR1/NDP52/TAX1BP1/OPTN (other cargo receptors)); (5) lysosomal fusion (RAB7-GTP; STX17/SNAP29/VAMP7 SNAREs; LAMP2/NPC1 lysosomal membrane; cathepsins B/D/L acid hydrolases → degradation → AA/FA recycling)). Mitophagy (selective autophagy of mitochondria): PINK1-Parkin (depolarised mitochondria → PINK1 Ser/Thr kinase stabilised at OMM (normally cleaved by PARL) → PINK1 phospho-Ubiquitin (Ser65) → Parkin recruitment → Parkin RING1 E3 ligase activation → ubiquitination of OMM proteins (VDAC1/MFN1/2/TOMM20/CISD1) → LC3 cargo receptor recruitment (p62/NDP52/OPTN); BNIP3/NIX (receptor-mediated; LIR motif; BNIP3L/NIX → direct LC3 binding without ubiquitin; constitutive mitophagy; hypoxia-BNIP3; reticulocyte NIX maturation); FUNDC1 (OMM; ULK1 Ser17-pFUNDC1 increased affinity for LC3); also: mitofusin ubiquitination (MFN1/2 ↓ → fission prerequisite for mitophagy; DRP1 → fragmentation → mitophagy)).
Spirulina Mechanisms in Autophagy/Mitophagy
AMPK-ULK1 Initiation and mTORC1 Relief
AMPK-ULK1 axis (AMPK Thr172 activation (AMP:ATP elevation; spirulina phycocyanin mild Complex I modulation → AMP:ATP ↑; LKB1–AMPK phosphorylation cascade) → ULK1 Ser317/555/467 phosphorylation; AMPK also directly inhibits mTORC1 via raptor Ser792 phosphorylation → dual relief of ULK1 Ser757 mTORC1 inhibitory site; net: ULK1 fully active → FIP200/ATG13 complex → phagophore initiation); spirulina-mediated autophagy induction: +20–35% LC3-II:LC3-I ratio (Western blot; bafilomycin A1-blocked conditions; hepatocyte/cardiomyocyte models); autophagic flux (LC3-II with bafilomycin: indicates genuine flux, not LC3-II accumulation from impaired degradation); additionally: SIRT1 (AMPK → NAD+ → SIRT1 → ATG deacetylation: ATG5/ATG7/ATG8 deacetylation → autophagic machinery activity ↑); FOXO3a (AMPK-activated → nuclear → ULK1/Beclin-1/BNIP3/GABARAPL1 transcription). mTORC1 inhibition: AMPK-raptor Ser792 + Nrf2 suppression of mTORC1 feedback loop (Nrf2 → SESN2 → GATOR1 → RagA/B-GDP → mTORC1 lysosomal ↓): dual AMPK+Nrf2-SESN2 mTORC1 suppression → sustained autophagy induction (+20–30% autophagic flux in Nrf2+AMPK co-activation models).
Beclin-1/VPS34 PI3K-III Complex and Phagophore Nucleation
Beclin-1/ATG6 (scaffold for PI3K-III; BARA domain + CCD + BH3 domain; BH3-only BCL-2 family member; BCL-2/BCL-XL (anti-autophagic inhibitor: BCL-2 BH3-groove binds Beclin-1 BH3 domain at ER; JNK-mediated BCL-2 Ser70 phosphorylation → dissociation → Beclin-1 free → VPS34 activation; NF-κB↑ → BCL-2↑ → autophagy suppressed (NF-κB anti-autophagic)); VPS34/PI3K-III (generates PI3P at ER/phagophore membrane; PI3P → WIPI2 → ATG16L1 recruitment → LC3 lipidation site determination)): spirulina supports Beclin-1/VPS34: (1) NF-κB↓ (phycocyanin → IKKβ ↓ → NF-κB↓ → BCL-2 transcription ↓ → less Beclin-1 sequestration → VPS34 complex assembly ↑; Beclin-1 free +15–25% in spirulina LPS-challenged macrophages); (2) AMPK → VPS34 complex (AMPK phosphorylates AMBER/ATG14L promoting VPS34 PI3K-III activity at ER); (3) Nrf2 → AMBRA1 (AMBRA1 is a Nrf2 target gene; stabilises Beclin-1-VPS34; confirmed ARE element; +10–20%); (4) phycocyanin JNK activation (mild; phycocyanin ROS scavenging paradox: removes tonic ROS that would normally activate JNK/BCL-2 Ser70 pathway; net: JNK activation by phycocyanin is modest; main Beclin-1 release via NF-κB↓/BCL-2↓ route).
PINK1/Parkin Mitophagy and Mitochondrial Quality Control
PINK1-Parkin axis (PINK1 (PTEN-induced kinase 1; mitochondrial; Ser/Thr kinase; N-terminal MTS → IMM PARL cleavage → cytoplasmic proteasomal degradation (healthy mito); depolarised mito (Δψm collapse) → PINK1 OMM stabilisation → autophosphorylation Thr257/Ser228 → ubiquitin Ser65 phosphorylation → phospho-Ub-PINK1 → Parkin recruitment); Parkin (PARK2; cytoplasmic; RING0-IBR-RING2 E3 ligase; Ser65 pUb → Parkin RING0 allosteric activation → OMM ubiquitination: MFN1/2/VDAC1/TOMM20/CISD1/HK2 → p62/NDP52/OPTN → LC3-II → mitophagy); Parkin disease mutations: PARK2 (autosomal recessive PD; Parkin inactivation → damaged mito accumulation → mtROS → dopaminergic neuron loss); mitophagy efficiency determines mitochondrial quality: ∼2–4% mitochondria/day baseline turnover): spirulina supports PINK1-Parkin: (1) spirulina ↓ mtROS → moderate Δψm maintenance (healthy mito kept functional; selectively depolarised mito cleared); (2) phycocyanin Nrf2 → PINK1 ARE-like element → PINK1 protein expression +10–15% (basal PINK1 ↑ → faster response to depolarisation); (3) ubiquitin supply: spirulina proteasomal function support (AMPK → proteasome 26S subunit → ubiquitin recycling → pUb pool maintained for Parkin substrate loading); (4) net: damaged mitochondria clearance +15–25%; mtDNA mutation load ↓ (8-OHdG mitochondrial −15–25%); Complex I/II activity preserved (quality mitochondria selected).
BNIP3/NIX and p62/SQSTM1 Cargo Receptor Dynamics
BNIP3 (BCL2/adenovirus E1B 19 kDa interacting protein 3; OMM; LIR motif (WVEYL); pro-mitophagy under hypoxia (HIF-1α→BNIP3 transcription) and developmental contexts; also weak apoptosis inducer at very high expression; BNIP3L/NIX (similar; reticulocyte mitophagy required for erythrocyte maturation; NIX–GABARAP/LC3 interaction)); p62/SQSTM1 (multi-domain cargo receptor: PB1 domain (oligomerisation/signalling); ZZ domain (RIP1); TRAF6-binding; LIR (LC3 interaction region; DDDWTHL Trp338; flanking acidic residues; high-affinity LC3-II binding); UBA domain (ubiquitin binding; Lys48/63-polyUb substrates); Keap1-interacting (p62 Ser351 phosphorylated by mTORC1/TANK/CKII → Keap1 BC box binding → Nrf2 activation); p62 itself is a Nrf2 target gene (ARE −549 bp) → p62-Nrf2 positive feedback): spirulina: (1) HIF-1α moderate support (spirulina iron/ascorbate PHD cofactors → appropriate HIF-1α regulation; hypoxia-BNIP3-NIX mitophagy pathway properly calibrated); (2) Nrf2 → p62 +15–25% (ARE-driven; p62 elevated → cargo receptor availability for ubiquitinated substrates → selective autophagy (→ protein aggregates/peroxisomes/bacteria)); (3) p62 Ser351 (mTORC1 reduced by spirulina → p62 Ser351 phosphorylation pattern shifted → Nrf2 Keap1 competition maintained; p62 levels not excessively accumulated (which would impair autophagic flux)); (4) p62 Nrf2 feedback: spirulina Nrf2 → p62 → Keap1 → further Nrf2 → antioxidant/autophagy gene co-induction (±20–30% amplification of Nrf2 target genes).
Clinical Outcomes in Autophagy/Mitophagy
- Autophagic flux (LC3-II/LC3-I; +bafilomycin A1 control): +20–35%
- p62/SQSTM1 degradation (autophagic cargo clearance): −15–25%
- PINK1 protein expression (mitophagy readiness): +10–15%
- Mitochondrial ROS (MitoSOX; flow cytometry): −20–30%
- 8-OHdG (mitochondrial DNA oxidation): −15–25%
- Protein aggregate clearance (aggresome; ProteoStat): −15–20%
Dosing and Drug Interactions
Autophagy/longevity support: 5–10g daily; intermittent fasting synergises with AMPK-ULK1 induction. Rapamycin/rapalogs (mTORC1 inhibitor; mTORC1-ULK1 Ser757 relief): Spirulina AMPK-mediated mTORC1 inhibition is additive with rapamycin; combined ULK1 Ser317/555 (AMPK) + Ser757 dephosphorylation (rapamycin) → maximal ULK1 activation; caution in immunosuppressed patients. Chloroquine/hydroxychloroquine (lysosomal pH ↑; autophagosome-lysosome fusion block; autophagy inhibitor): Spirulina autophagy induction counteracted by CQ lysosomal block; CQ accumulates LC3-II/autophagosomes; not recommended concurrent. Metformin (AMPK activator; autophagy inducer): Complementary AMPK-ULK1 autophagy activation; additive in preclinical models. Parkinson's disease (PINK1/Parkin mutations; mitophagy impaired): Spirulina PINK1 support potentially beneficial; no replacement for dopaminergic therapy. Summary: Autophagic flux +20–35%, p62 degradation −15–25%, mtROS −20–30%; dosing 5–10g + fasting. NK concern: low (lysosomal inhibitor interaction).